As early results have indicated that 90Y-IT consolidation has a favorable tolerability profile, with low infection rates and a manageable hematologic toxicity, we carried out this study with CHOP plus rituximab followed by 90Y-IT in untreated elderly DLBCL patients, also reducing the number of CHOP cycles from six to four. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.